Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Reported net loss was $9.0 million, or $0.19 per basic and diluted share, for the three months ended September 30, 2025, compared to $10.7 million, or $0.29 per basic share and diluted share, for the ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to ...

Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC− Supports the planned Phase 1 cohort of ...

CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

President Donald Trump put pharmaceutical CEOs on notice, demanding they lower drug prices or he promised to get involved. He penned a letter to 17 CEOs in July, outlining what he wants from the ...

Phase 1 data demonstrate activation of tumor-selectiveinterferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to be fruitful, as demonstrated through its Keynote-B96 trial in ovarian ...